Orlistat
CAS NO: 96829-58-2
Molecular Formula: C29H53NO5
Molecular Weight: 495.73
H bond acceptors: 6
H bond donors: 1
Freely Rotating Bonds: 23
Polar Surface Area: 72.91 ?2
Index of Refraction: 1.469
Molar Refractivity: 141.57 cm3
Molar Volume: 507.5 cm3
Surface Tension: 35.6 dyne/cm
Density: 0.976 g/cm3
Flash Point: 326.3 °C
Melting Point: <50 °C
Enthalpy of Vaporization: 91.36 kJ/mol
Boiling Point: 615.9 °C at 760 mmHg
Vapour Pressure: 4.23E-15 mmHg at 25°C
Storage temp: 2-8°C
Solubility: DMSO: 19 mg/mL
Appearance: Off-White Solid.
Product Description
Orlistat is a drug designed to treat obesity. It is mainly used for preventing the absorption of fats from the human diet, thereby reducing caloric intake. Besides, it is intended for use in conjunction with a physician-supervised reduced-calorie diet.
Orlistat is a drug that promotes loss of weight by preventing the digestion and absorption of fat in food. In the intestine, an enzyme called lipase (produced primarily by the pancreas) breaks apart fat in food so that it can be absorbed into the body. Orlistat blocks the action of lipase and thereby prevents the breakup and absorption of fat. Orlistat blocks absorption of about 25% of the fat in a meal. The unabsorbed fat is excreted in the stool. The FDA approved Orlistat by prescription in 1999. alli, a lower dose formulation of orlistat, was approved for purchase without a prescription "over the counter" in 2007.
Applications:
Orlistat is used for the treatment of obesity.The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body mass.After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost.
The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%).Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).
1. Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body fat. After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost.
2. The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%). Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).
competitive advantage :
1. Best prices with satisfied quality ,Great quality and purity
2. Perfect Packing and safe ,fast delivery.
we have sold these products for many years , our enrich experience make our products have a high rate to pass your country custom.
3 good after-sales service
We can provide the easier way to help our regular clients to convert steroid powders to injectiable oil
Permanent link: http://www.vvchem.com/sell/cas:96829-58-2,3319221.html
China
